NDMA Problems Leads To Additional Metformin Recalls
Problems with N-nitrosodimethylamine (NDMA) contamination has resulted in another metformin recall, impacting additional versions of the generic diabetes drug sold by Nostrum Laboratories, which may contain dangerous levels of the toxic chemical byproduct.
The FDA announced a Metformin HCI Extended Release Tablets recall expansion on January 25, indicating Nostrum Laboratories, Inc. had discovered another lot of its generic diabetes drug tablets contained levels of NDMA which exceeded the acceptable daily intake limit of 96 nanograms (ng) per day. It is the second expansion of the Nostrum NDMA metformin recall, which was first announced in November.
NDMA is considered a human carcinogen, which can be a byproduct of the drug manufacturing process or produced as an inherent byproduct of certain pharmaceutical ingredients.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
In recent years, detection of the chemical has resulted in widespread Zantac recalls and valsartan recalls, and users of the popular heartburn and blood pressure medications have reported developing various types of cancer following long-term use, including breast cancer, bladder cancer, stomach cancer, testicular cancer and other injuries.
The recall affects Metformin HCI Extended Release Tablets, USP 750 mg, with NDC 29033-056-01 and lot number MET200601, with expiry dates 07/2022. The recalled tablets are off-white and oblong, debossed with “NM7”.
Nostrum Laboratories, Inc. indicates it will notify distributors by letter, and is arranging for the return of all of the recalled products, according to the recall notice.
Metformin NDMA Recalls
This action marks the latest in a series of recalls impacting generic metformin pills manufactured by a number of different companies.
In December 2019, reports first warned about the potential risk of metformin NDMA contamination problems, after some versions of the drug sold outside the United States tested positive for the chemical. However, the FDA indicated at the time that testing of products distributed in the U.S. found that the NDMA levels in metformin were undetectable or below federal limits for exposure to the chemical.
In March 2020, the independent online pharmacy Valisure filed a citizen’s petition urging the FDA to recall metformin, after independent testing found levels of NDMA in certain pills was higher than the agency’s recommended daily exposure threshold of 96 nanograms.
Since then, the FDA says it has confirmed some of the Valisure findings, resulting in a number of separate recalls for metformin pills that were found to contain higher than acceptable levels of NDMA. A number of consumers have now filed metformin lawsuits against manufacturers of the generic drugs, indicating they developed cancer from the tainted diabetes medication.
The FDA requests any healthcare providers or consumers who experience adverse reactions or quality problems when using the recalled drugs report the incident to the FDA MedWatch Adverse Event Reporting program.
YasminOctober 17, 2021 at 3:45 pm
I’ve been taking this drug for quite a few years now am I going to get cancer It’s a number of drugs that has put me in jeopardy of cancer now
"*" indicates required fields
More Top Stories
Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.
More than 775 Exactech lawsuits have been filed in federal and state courts as parties work toward a plan for bellwether early test trials.
A federal judge has announced he will soon begin remanding 3M earplug lawsuits back to their originating districts for trials over claims of veteran hearing loss.